NHS England has started offering Fampridine, the first medicine specifically approved to improve walking in eligible adults with multiple sclerosis (MS).
- NHS England has introduced Fampridine, the first medicine to improve walking in eligible people with MS
- Around 5,000 patients could benefit, with treatment continuing only if it shows clear improvement
- Clinical trials and recent real-world studies support its role in improving mobility for many patients
NHS England has begun rolling out Fampridine as a routine treatment for eligible adults with multiple sclerosis (MS) who have difficulty walking.
According to NHS England, the medicine is the first licensed drug specifically recommended to improve walking in people with MS and is expected to benefit around 5,000 patients during its first year of availability (1✔ ✔Trusted Source
Thousands with MS to get “life-changing” drug on NHS to help them walk more freely
)(2✔ ✔Trusted Source
Prolonged-released (PR) fampridine as a treatment of adults with Multiple Sclerosis and associated walking impairment
).
Walking problems are one of the most common causes of disability in MS. A recent New England Journal of Medicine review explains that damage to myelin—the protective covering around nerve fibers—slows the messages traveling between the brain and the rest of the body (3✔ ✔Trusted Source
Advances in Multiple Sclerosis
This can lead to muscle weakness, poor balance, fatigue, and difficulty walking, making everyday activities increasingly challenging.
Unlike medicines that slow the disease itself, fampridine is designed to improve a person’s ability to walk. An expert review explains that the medicine helps damaged nerves send electrical signals more effectively, allowing some people with MS to walk faster and more confidently b> (4✔ ✔Trusted Source
Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
Advertisement
How Will the NHS Rollout of Fampridine Help People With MS?
According to NHS England, Fampridine will be offered to adults whose walking problems fall within a defined disability range. Before continuing treatment, every patient must complete a short trial period and show a measurable improvement in walking. This ensures the medicine is used only by people who are likely to benefit from it.
Although the medicine does not work for everyone, many eligible patients experience meaningful improvements in walking and day-to-day mobility.
Together, these studies explain why NHS England decided to make fampridine available as a routine treatment for eligible patients.
| What the Evidence Shows | What It Means for Patients |
|---|---|
| NHS England expects around 5,000 people to receive the treatment in the first year. | Thousands of eligible people with MS could gain access to a new walking treatment through the NHS. |
| NHS clinical evidence found that about 43% of patients walked faster after taking fampridine. | The medicine helps many people, but not everyone, so patients are carefully assessed before continuing treatment. |
| The NHS commissioning policy recommends the medicine for adults with an EDSS score of 4–7, followed by a 2–4 week trial before reassessment. | Doctors check whether the medicine is working before deciding if treatment should continue. |
| An expert review reported that people who respond may also notice improvements in endurance, balance, and quality of life alongside better walking. | Better walking can make everyday tasks easier and improve independence for some patients. |
Advertisement
How Does Fampridine Help Improve Walking in Multiple Sclerosis?
Unlike medicines that help slow the progression of multiple sclerosis (MS), fampridine targets one specific symptom—walking difficulty.
The drug blocks potassium channels in damaged nerve fibres, helping electrical signals travel more effectively through nerves that have lost their protective myelin coating.
Fampridine does not stop MS from progressing or repair damaged nerves. Instead, it may help some people (5✔ ✔Trusted Source
Fampridine (Fampyra)
- Walk faster and more steadily
- Feel more confident while walking
- Find everyday activities like shopping or climbing stairs easier
Experts also report that some people who respond to treatment may experience additional benefits, including:
- Better endurance
- Improved balance
- Greater confidence while moving
- Improved quality of life
However, these benefits vary from person to person, and not everyone responds to the medicine.
Advertisement
Why Is Medicine Alone Not Enough for Better Mobility?
Experts say that Fampridine works best when combined with rehabilitation and supportive care, rather than as a standalone treatment.
Managing multiple sclerosis (MS) involves a combination of disease-modifying therapies, symptom management, and lifestyle support to help people stay active and independent.
The following strategies can further improve mobility (6✔ ✔Trusted Source
8 Steps to Better Mobility When You Have MS
- Physical therapy to strengthen muscles and improve movement
- Regular exercise to build balance and endurance
- Walking aids, when needed, to improve safety and reduce the risk of falls
Combining rehabilitation with fampridine may provide greater improvements than either approach alone. Regular follow-up is important because mobility needs can change as MS progresses.
For many people with MS, better mobility means more than walking faster. It can help them:
- Carry out daily activities more easily
- Stay active at work or in social settings
- Maintain greater independence and confidence
I think scrapping the table is the right decision here. There aren’t enough unique quantitative findings to justify a separate table, and it interrupts the flow. This H2 will read much better with a short intro followed by concise bullets.
Can Fampridine Improve More Than Just Walking?
While fampridine is approved to improve walking, research suggests that some people who respond to the medicine may also experience broader mobility and quality-of-life benefits. However, these improvements vary from person to person and are not guaranteed.
Patients who respond to fampridine may experience the following:
- Better walking speed and stability
- Improved balance and endurance
- Better lower-limb function
- Greater confidence while walking
- Improved quality of life
- Easier everyday activities, such as shopping, climbing stairs, or walking longer distances
A recent publication also supports these findings. The study followed 197 adults receiving fampridine in routine clinical practice and found that (7✔ ✔Trusted Source
“Effectiveness and associated factors of response to Fampridine in multiple sclerosis: A prospective observational study from an expert center”
):
- 59% of patients responded to treatment.
- The medicine showed benefits in real-world healthcare settings, not just clinical trials.
- Researchers identified factors that may help predict which patients are more likely to benefit.
- Fampridine was generally well tolerated during the study.
Because MS affects everyone differently, doctors reassess patients after starting treatment and continue the medicine only if there is a clear improvement in walking and mobility.
Frequently Asked Questions
Q: What is fampridine used for?
A: Fampridine is a prescription medicine that helps improve walking in some adults with multiple sclerosis who have difficulty walking.
Q: Does fampridine cure multiple sclerosis?
A: No. It does not cure MS or stop the disease from progressing. It is used to improve walking ability in eligible patients.
Q: Who can receive fampridine through the NHS?
A: According to NHS England, it is offered to eligible adults with MS who meet specific clinical criteria and show improvement after an initial treatment period.
Q: How quickly do doctors know if the medicine is working?
A: Walking is usually reassessed after about two to four weeks of treatment. If there is no meaningful improvement, the medicine is generally discontinued.
Q: Does fampridine help everyone with MS?
A: No. Clinical studies show that some patients respond well, while others do not. This is why treatment is continued only for people who clearly benefit.
Q: Can patients continue physiotherapy while taking fampridine?
A: Yes. Experts recommend using fampridine alongside rehabilitation, exercise, and other supportive therapies to help maintain mobility.
Q: Why is this NHS rollout important?
A: It gives eligible people with MS access to the first NHS-funded medicine specifically approved to improve walking, offering a new option to support mobility and independence.
References:
- Thousands with MS to get “life-changing” drug on NHS to help them walk more freely – (https://www.england.nhs.uk/2026/07/thousands-ms-life-changing-drug-nhs-help-walk-more-freely/)
- Prolonged-released (PR) fampridine as a treatment of adults with Multiple Sclerosis and associated walking impairment – (https://www.england.nhs.uk/wp-content/uploads/2026/07/2341-commissioning-policy-prolonged-released-fampridine.pdf)
- Advances in Multiple Sclerosis – (https://www.nejm.org/doi/full/10.1056/NEJMra2501195)
- Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting – (https://pmc.ncbi.nlm.nih.gov/articles/PMC6174649/#)
- Fampridine (Fampyra) – (https://www.mssociety.org.uk/living-ms/treatments-and-therapies/drug-treatment-ms-symptoms/fampridine-fampyra)
- 8 Steps to Better Mobility When You Have MS – (https://www.msviewsandnews.org/8-steps-to-better-mobility-when-you-have-ms/)
- “Effectiveness and associated factors of response to Fampridine in multiple sclerosis: A prospective observational study from an expert center” – (https://www.sciencedirect.com/science/article/abs/pii/S2211034825006078)
Source-Medindia